Literature DB >> 27504064

Ceftazidime-Avibactam (Avycaz): For the Treatment of Complicated Intra-Abdominal and Urinary Tract Infections.

Juan F Mosley, Lillian L Smith, Crystal K Parke, Jamal A Brown, Alton L Wilson, Lydia V Gibbs.   

Abstract

Ceftazidime-avibactam (Avycaz) for the treatment of complicated infections.

Entities:  

Year:  2016        PMID： 27504064      PMCID： PMC4959616     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  2 in total

Review 1.  Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria.

Authors:  Neelam Taneja; Harsimran Kaur
Journal:  Microbiol Insights       Date:  2016-03-20

Review 2.  Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes.

Authors:  David van Duin; Keith S Kaye; Elizabeth A Neuner; Robert A Bonomo
Journal:  Diagn Microbiol Infect Dis       Date:  2013-01-03       Impact factor: 2.803
  2 in total
  8 in total

1.  Structure-Based Analysis of Boronic Acids as Inhibitors of Acinetobacter-Derived Cephalosporinase-7, a Unique Class C β-Lactamase.

Authors:  Alexandra A Bouza; Hollister C Swanson; Kali A Smolen; Alison L VanDine; Magdalena A Taracila; Chiara Romagnoli; Emilia Caselli; Fabio Prati; Robert A Bonomo; Rachel A Powers; Bradley J Wallar
Journal:  ACS Infect Dis       Date:  2017-12-08       Impact factor: 5.084

2.  Cost-effectiveness of ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae bacteremia and pneumonia.

Authors:  Matthew S Simon; Maroun M Sfeir; David P Calfee; Michael J Satlin
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

3.  Structural analysis of avibactam-mediated activation of the bla and mec divergons in methicillin-resistant Staphylococcus aureus.

Authors:  J Andrew N Alexander; Mariia Radaeva; Dustin T King; Henry F Chambers; Artem Cherkasov; Som S Chatterjee; Natalie C J Strynadka
Journal:  J Biol Chem       Date:  2020-06-09       Impact factor: 5.157

Review 4.  Optimal Management of Complicated Infections in the Pediatric Patient: The Role and Utility of Ceftazidime/Avibactam.

Authors:  Matteo Bassetti; Maddalena Peghin; Alessio Mesini; Elio Castagnola
Journal:  Infect Drug Resist       Date:  2020-06-12       Impact factor: 4.003

5.  1,2,3-Triazolylmethaneboronate: A Structure Activity Relationship Study of a Class of β-Lactamase Inhibitors against Acinetobacter baumannii Cephalosporinase.

Authors:  Emilia Caselli; Francesco Fini; Maria Luisa Introvigne; Mattia Stucchi; Magdalena A Taracila; Erin R Fish; Kali A Smolen; Philip N Rather; Rachel A Powers; Bradley J Wallar; Robert A Bonomo; Fabio Prati
Journal:  ACS Infect Dis       Date:  2020-06-24       Impact factor: 5.084

Review 6.  Antibiotic resistance breakers: current approaches and future directions.

Authors:  Mark Laws; Ali Shaaban; Khondaker Miraz Rahman
Journal:  FEMS Microbiol Rev       Date:  2019-09-01       Impact factor: 16.408

7.  Natural variants modify Klebsiella pneumoniae carbapenemase (KPC) acyl-enzyme conformational dynamics to extend antibiotic resistance.

Authors:  Catherine L Tooke; Philip Hinchliffe; Robert A Bonomo; Christopher J Schofield; Adrian J Mulholland; James Spencer
Journal:  J Biol Chem       Date:  2020-12-03       Impact factor: 5.157

8.  Evolutionary Trajectories toward Ceftazidime-Avibactam Resistance in Klebsiella pneumoniae Clinical Isolates.

Authors:  Alessandra Carattoli; Gabriele Arcari; Giulia Bibbolino; Federica Sacco; Dario Tomolillo; Federica Maria Di Lella; Maria Trancassini; Luigi Faino; Mario Venditti; Guido Antonelli; Giammarco Raponi
Journal:  Antimicrob Agents Chemother       Date:  2021-08-02       Impact factor: 5.191
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.